IL268567A - BCMA, NKG2D and CD16 binding proteins - Google Patents
BCMA, NKG2D and CD16 binding proteinsInfo
- Publication number
- IL268567A IL268567A IL268567A IL26856719A IL268567A IL 268567 A IL268567 A IL 268567A IL 268567 A IL268567 A IL 268567A IL 26856719 A IL26856719 A IL 26856719A IL 268567 A IL268567 A IL 268567A
- Authority
- IL
- Israel
- Prior art keywords
- nkg2d
- proteins binding
- binding bcma
- bcma
- proteins
- Prior art date
Links
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL268567A true IL268567A (en) | 2019-09-26 |
Family
ID=63107848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268567A IL268567A (en) | 2017-02-10 | 2019-08-07 | BCMA, NKG2D and CD16 binding proteins |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (OSRAM) |
| EP (1) | EP3579876A4 (OSRAM) |
| JP (2) | JP7257323B2 (OSRAM) |
| KR (2) | KR20190115469A (OSRAM) |
| CN (1) | CN110461361A (OSRAM) |
| AU (1) | AU2018219348A1 (OSRAM) |
| BR (1) | BR112019016424A2 (OSRAM) |
| CA (1) | CA3054642A1 (OSRAM) |
| IL (1) | IL268567A (OSRAM) |
| MA (1) | MA47465A (OSRAM) |
| MX (1) | MX2019009566A (OSRAM) |
| MY (1) | MY205850A (OSRAM) |
| SG (1) | SG11201907253VA (OSRAM) |
| WO (1) | WO2018148566A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6698546B2 (ja) * | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| MY205850A (en) * | 2017-02-10 | 2024-11-15 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| BR112020003654A2 (pt) * | 2017-08-23 | 2020-11-17 | Dragonfly Therapeutics, Inc. | proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12384851B2 (en) * | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| TW202100184A (zh) * | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體－藥物結合物及使用方法 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| MX2022015374A (es) | 2020-06-05 | 2023-01-16 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso. |
| CN112029001B (zh) * | 2020-09-02 | 2022-09-06 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| JP2023545099A (ja) * | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| US20240174768A1 (en) | 2021-03-03 | 2024-05-30 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2022212470A2 (en) * | 2021-03-31 | 2022-10-06 | Janssen Biotech, Inc. | Materials and methods for immune effector cells redirection |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| AU2007257692B2 (en) * | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| WO2009089004A1 (en) * | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| SG10201602371VA (en) * | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| CN107759686A (zh) * | 2012-05-30 | 2018-03-06 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| EP2953974B1 (en) * | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| US20140323315A1 (en) * | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| DK3280432T3 (da) * | 2015-04-06 | 2021-04-26 | Subdomain Llc | Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| JP2020506971A (ja) * | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| MY205850A (en) * | 2017-02-10 | 2024-11-15 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019016424A2 (pt) | 2020-04-07 |
| SG11201907253VA (en) | 2019-09-27 |
| MY205850A (en) | 2024-11-15 |
| RU2019127910A (ru) | 2021-03-10 |
| MA47465A (fr) | 2019-12-18 |
| CA3054642A1 (en) | 2018-08-16 |
| CN110461361A (zh) | 2019-11-15 |
| WO2018148566A1 (en) | 2018-08-16 |
| JP2020507328A (ja) | 2020-03-12 |
| JP2023029988A (ja) | 2023-03-07 |
| KR20240078657A (ko) | 2024-06-04 |
| RU2019127910A3 (OSRAM) | 2021-06-15 |
| KR20190115469A (ko) | 2019-10-11 |
| US20190375838A1 (en) | 2019-12-12 |
| AU2018219348A1 (en) | 2019-08-29 |
| EP3579876A1 (en) | 2019-12-18 |
| MX2019009566A (es) | 2020-01-20 |
| JP7257323B2 (ja) | 2023-04-13 |
| EP3579876A4 (en) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
| IL268790A (en) | CD33, NKG2D and CD16 binding proteins | |
| IL268755B2 (en) | Proteins that bind her2, nkg2d, and cd16 | |
| IL281305A (en) | Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1 | |
| SG11202000632QA (en) | Proteins binding nkg2d, cd16 and flt3 | |
| IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
| IL277398A (en) | PD-L1 binding epimers and related uses thereof | |
| IL323220A (en) | Engineered DNA-binding proteins | |
| IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
| IL281323A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| IL292261A (en) | Proteins that bind nkg2d, cd16 and flt3 | |
| IL273206A (en) | Proteins that bind NKG2D, CD16, and C-type lectin-like molecule (CLL-1) | |
| IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
| SG11202100883SA (en) | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use | |
| IL268766A (en) | Proteins that bind NKG2D, CD123, and CD16 | |
| IL272706A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| EP3630181A4 (en) | NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN | |
| EP3630169A4 (en) | NKG2D, CD16, AND TUMOR-ASSOCIATED PROTEIN | |
| HK40014030A (en) | Proteins binding bcma, nkg2d and cd16 | |
| ZA201905273B (en) | Proteins binding psma, nkg2d and cd16 | |
| HK40030226A (en) | Proteins binding nkg2d, cd16 and flt3 | |
| HK40019178A (en) | Proteins binding psma, nkg2d and cd16 | |
| HK40014039A (en) | Proteins binding cd33, nkg2d and cd16 | |
| HK40019734A (en) | Proteins binding cd123, nkg2d and cd16 | |
| HK40055054A (en) | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |